Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Harrow Inc

HROW ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: BUY

Last Close

$40.03

▲ +2.98%

Market Cap $1.50B · Vol 173.16K

Key Metrics

P/E Ratio

N/A

FWD: 27.68

Market Cap

$1.50B

Small Cap

Div Yield

N/A

EPS Growth

-66.66%

YoY

RSI (14)

64.79

Momentum

Beta

0.25

vs Market

52W High

$54.81

26.97% below

52W Low

$28.55

40.21% above

Volume

173.16K

Avg 193.41K

P/B

34.78

Price-to-book

ROE

N/A

Return on equity

Free Float

84.59%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Harrow Inc (HROW) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does HROW pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.01%

-3.24%

+29.71%

-16.06%

YTD

-18.31%

+0.05%

+132.87%

+342.81%

Financials & Valuation

TTM · Annual

Total Revenue	$272.30M
Net Income	$-5,139,000.00
Revenue Growth (YoY)	+10.85%
Gross Margin	75.05%
Operating Margin	11.21%
Net Profit Margin	-1.89%
ROE	N/A
ROA · ROIC	-0.35% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	27.68
PEG Ratio	N/A
P/S	6.61
P/B	34.78
P/FCF	42.12
EPS Growth	-66.66%
Outstanding Shares	37.49M

Technical Indicators

50-Day SMA	$40.59
200-Day SMA	$41.12
RSI (14)	64.79
Beta	0.25
52-Week High	$54.81
52-Week Low	$28.55

Volume Today	173.16K
Avg Daily Volume (30D)	193.41K
Relative Volume	0.90x
Volatility (10D)	26.68
Volatility (30D)	48.70
Free Float	84.59%

Analyst Consensus

BUY

Current Price $40.03

Mean Target $66.00

52W Low$28.55 52W High$54.81

Current

Target

$28.55 $54.81

Current Analyst target

+64.88% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SSTRN9

ISINUS4158581094

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.